Epigenomics AG Demonstrates Feasibility of Convenient Blood Test for Lung Cancer Detection in Clinical Study
Epigenomics AG takes a further step towards launching a convenient blood-based lung cancer screening test that could considerably improve the early detection of lung cancer, the most common cause of cancer-related death. The molecular diagnostics company today announced positive data resulting from a clinical study as part of its lung cancer screening test development program.
This entry was posted on Wednesday, June 27th, 2007 at 9:15 am and is filed under Research, Early Detection. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.